TWiV 889: COVID-19 clinical update #110 with Dr. Daniel Griffin
In COVID-19 clinical update #110, Dr. Griffin covers hospital admissions during variant outbreaks, viral load in vaccinated and unvaccinated individuals, predictive capacity of symptoms in children, comparison of antigen tests, incidence of myocarditis after vaccination, steroids during replication phase, Paxlovid efficacy and safety, fluvoxamine, sabizabutin, colchicine, and prevalence of infection in Africa. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Hospital admissions during Omicron and Delta variant outbreaks (Lancet) Viral load in unvaccinat...
Source: This Week in Virology - MP3 Edition - April 16, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 820: COVID-19 clinical update #85 with Dr. Daniel Griffin
In COVID-19 clinical update #85, Dr. Griffin reviews cases and deaths by vaccination status, mRNA vaccine effectiveness in 12-18 year olds, standard and extended dosing of mRNA vaccines, immune responses after vaccination, Moderna booster dose approved, giving monoclonals at home, no benefit from colchicine, and IFN does not help remdesivir. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Guidelines on COVID-19 drugs (WHO) Holiday celebrations (CDC) COVID-19 cases and deaths by vaccination status (CDC) Effectiveness o...
Source: This Week in Virology - MP3 Edition - October 23, 2021 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 820: COVID-19 clinical update #85 with Dr. Daniel Griffin
In COVID-19 clinical update #85, Dr. Griffin reviews cases and deaths by vaccination status, mRNA vaccine effectiveness in 12-18 year olds, standard and extended dosing of mRNA vaccines, immune responses after vaccination, Moderna booster dose approved, giving monoclonals at home, no benefit from colchicine, and IFN does not help remdesivir. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Guidelines on COVID-19 drugs (WHO) Holiday celebrations (CDC) COVID-19 cases and deaths by vaccination status (CDC) Effectiveness o...
Source: This Week in Virology - MP3 Edition - October 23, 2021 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 764: COVID-19 clinical update #65 with Dr. Daniel Griffin
In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Effects of vaccines and NPIs (JAMA) Guidance on summer camps (CDC) Antibody testing not recommended (FDA) Antige...
Source: This Week in Virology - MP3 Edition - June 5, 2021 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 713: COVID-19 clinical update #47 with Dr. Daniel Griffin
In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Novavax vaccine phase 3 results (Novavax) J&J vaccine phase 3 results (J&J) COVID-19 and transmission in K-12 schools (MMWR) Lilly mAb therapy (NEJM) Regeneron mAb prophylaxis (Regeneron) Colchicine for COVID-19 (Cardiol...
Source: This Week in Virology - MP3 Edition - January 30, 2021 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Effect of darapladib on post-ACS events, colchicine for postpericardiotomy afib, sickle cell disease management guidelines, and more.
Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 10, 2014 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - September 9, 2014 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
JAMA: 2012-11-28, Vol. 308, No. 20, Author in the Room ™ Audio Interview
Interview with Robert H. Shmerling, MD, author of Management of Gout: A 57-Year-Old Man With a History of Podagra, Hyperuricemia, and Mild Renal Insufficiency. Summary Points:
Risk factor modification: alcohol intake, excess weight, diet, medications (although overall impact on gout uncertain).
Acute gout can be treated with NSAIDs, colchicine, corticosteroids, or a combination of these.
Urate-lowering treatment to prevent attacks and tophi is appropriate for certain patients with gout. (In my opinion, allopurinol is the best initial choice to suppress uric acid.)
Urate-lowering treatment should suppress uric acid to 6.0 ...
Source: JAMA Author in the Room - January 17, 2013 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA: 2012-11-28, Vol. 308, No. 20, Author in the Room™ Audio Interview
Interview with Robert H. Shmerling, MD, author of Management of Gout: A 57-Year-Old Man With a History of Podagra, Hyperuricemia, and Mild Renal Insufficiency. Summary Points:
Risk factor modification: alcohol intake, excess weight, diet, medications (although overall impact on gout uncertain).
Acute gout can be treated with NSAIDs, colchicine, corticosteroids, or a combination of these.
Urate-lowering treatment to prevent attacks and tophi is appropriate for certain patients with gout. (In my opinion, allopurinol is the best initial choice to suppress uric acid.)
Urate-lowering treatment should suppress uric acid to 6.0 ...
Source: JAMA Author in the Room - January 17, 2013 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
